Ewing Sarcoma: Understanding Your Pathology Report

Section Editor: Bibianna Purgina, MD FRCPC
September 11, 2026

Ewing sarcoma is an uncommon, fast-growing cancer that most often starts in bone and less often in the soft tissues. It belongs to a group of cancers called sarcomas, which arise from connective tissues such as bone, muscle, and fat. It is made of small, very immature-looking cells and is driven by a single genetic change.

That genetic change is what defines the diagnosis. Several other tumors look almost identical under the microscope but carry different changes, and clinicians now recognize them as separate diseases that behave differently. This article explains what appears on an Ewing sarcoma pathology report, why the molecular result matters so much, and how the treatment response is measured.

Where does Ewing sarcoma develop, and who gets it?

Ewing sarcoma most often develops in the long bones of the leg and arm, particularly the thigh bone, shin bone, and upper arm bone. It also frequently involves the pelvis and the ribs. Within a long bone, it usually arises in the shaft rather than at the end, which is the opposite of where osteosarcoma typically starts.

In roughly 10 to 15 percent of cases, the tumor arises outside bone, in the soft tissues. This is called extraskeletal Ewing sarcoma and can occur almost anywhere.

It is the second most common malignant bone tumor in children and young adults, after osteosarcoma. Close to 8 in 10 patients are under 20 at diagnosis, with the peak in the teenage years, and it is slightly more common in males. Incidence is substantially lower in people of African and East Asian ancestry than in people of European ancestry. This appears to relate to inherited differences in a region of DNA that the abnormal protein described below binds to.

What are the symptoms of Ewing sarcoma?

Pain at the site of the tumor. Often worsening over weeks or months, and frequently mistaken for a sports injury in an active teenager.
Swelling or a lump. Sometimes warm and tender, which can also suggest an infection.
A fracture. The bone breaks because the tumor has weakened it.
Fever and fatigue. More common than in most bone tumors, and part of why Ewing sarcoma is sometimes first treated as an infection.

About one quarter of patients already have metastatic disease when the diagnosis is made, most often in the lungs, and symptoms may relate to those sites as well.

What causes Ewing sarcoma?

Ewing sarcoma is caused by a genetic rearrangement inside the tumor cells, in which pieces of DNA break and rejoin in the wrong places. This creates a fusion gene, a single gene made from parts of two others.

The fusion produces an abnormal protein that acts like a switch stuck in the on position, turning growth-related genes on and off at the wrong times. In roughly 85 percent of cases,s the fusion joins EWSR1 to FLI1, and in about another 10 percent,t it joins EWSR1 to ERG. Other combinations occur, but all of them join a gene from one family, usually EWSR1, to a gene from a second family called the ETS family.

Almost all cases happen by chance. Ewing sarcoma is not inherited, and unlike osteosarcoma, oma it is not associated with any common inherited cancer syndrome. Genetic testing of a blood sample is therefore not routinely recommended after this diagnosis.

How is the diagnosis made?

Diagnosing Ewing sarcoma requires imaging, microscopic examination, and molecular testing together. None of the three is sufficient on its own.

X-rays often show a poorly defined area of bone destruction with layers of new bone formation around it, sometimes described as an onion-skin appearance. A large soft tissue mass alongside the bone is usual. MRI, CT, and PET scans then determine the tumor size and whether it has spread.

Under the microscope, Ewing sarcoma is made of sheets of small round cells that look very similar to one another. The nuclei are round with finely textured chromatin, the cytoplasm is scant and often clear, and the borders between cells are hard to make out. After chemotherapy, much of the tumor may be dead and replaced by scar-like tissue.

As with osteosarcoma, the biopsy site matters. The needle track has to be removed with the tumor at the definitive operation, so the biopsy is best performed at the center that will carry out the surgery.

Immunohistochemistry

Immunohistochemistry uses antibodies to detect proteins in the tumor cells. In Ewing sarcoma, it supports the diagnosis but does not confirm it.

Nearly all Ewing sarcomas show strong, even staining for CD99 around the outside of the cells. This is a sensitive finding, meaning it is almost always present, but it is not specific, because several other small round cell tumors are also CD99 positive. A second protein, NKX2-2, is usually positive and more specific. Some tumors also express keratins or nerve-related proteins, which can confuse the diagnosis.

Because no stain is conclusive, molecular testing is what settles the diagnosis.

Molecular testing and the fusion gene

Molecular testing identifies the fusion gene and is generally required to confirm a diagnosis of Ewing sarcoma. Two approaches are used, and the difference between them matters.

FISH uses fluorescent probes to show whether the EWSR1 gene has been broken. It is fast and widely available, but it has an important limitation: it shows that EWSR1 is rearranged without showing what it has joined to. EWSR1 is rearranged in several unrelated tumors, so a result reading only “EWSR1 rearrangement detected” does not by itself establish Ewing sarcoma.

RNA sequencing, often part of a next-generation sequencing panel, identifies both partners and names the fusion, for example EWSR1::FLI1. This is why sequencing has increasingly replaced FISH alone. If your report gives an EWSR1 result without naming a partner gene, it is reasonable to ask whether it identified the partner.

Tumors that look like Ewing sarcoma but are not

This is the most important change in how these tumors have been understood, and it affects what your diagnosis means.

Tumors that were once grouped as the Ewing sarcoma family, or as Ewing-like sarcomas, have since been separated. The World Health Organization classification of soft tissue and bone tumors, 5th edition, published in 2020, made this change. That classification recognizes four distinct diseases, all made of small round cells and all looking similar under the microscope.

Ewing sarcoma. Defined by a fusion joining EWSR1 or a related gene to a gene in the ETS family, most often FLI1. This article describes this disease.
CIC-rearranged sarcoma. Usually arises in soft tissue rather than bone, grows quickly, and responds less well to the chemotherapy used for Ewing sarcoma.
Sarcoma with BCOR genetic alterations. Seen most often in adolescent boys, usually in the long bones or pelvis.
Round cell sarcoma with an EWSR1 fusion to a non-ETS partner. Defined by the partner gene being outside the ETS family.

These are treated as separate diseases because they respond differently to treatment and carry different outlooks. If your tumor was called Ewing sarcoma or a Ewing-like sarcoma some years ago, it is worth asking whether molecular testing was done. It is also worth asking which of these four categories applies.

Why Ewing sarcoma is not graded

Most cancers are graded based on how abnormal the cells look. Ewing sarcoma is not graded, because every Ewing sarcoma is high grade by definition. The cells are uniformly immature, and small differences between one tumor and another do not predict behavior.

Prognosis and treatment therefore rest on other things: whether the tumor has spread at diagnosis, its size and location, and how well it responds to chemotherapy.

Treatment response

Chemotherapy is given before surgery in almost all cases. When the tumor is removed, the pathologist examines it to determine how much is necrotic, meaning dead and replaced by scar-like tissue.

The threshold for Ewing sarcoma is stricter than for most cancers. A good response means 100 percent necrosis, with no living tumor cells remaining anywhere in the specimen. Any living tumor cells count as a poor response, even when most of the tumor is dead. By comparison, osteosarcoma uses 90 percent as its threshold, so the two are not directly comparable if you are reading about both.

A complete response is associated with a lower risk of the cancer returning. A poor response does not mean treatment has failed, and it does not change the diagnosis. It is one of several pieces of information used to plan what follows.

Surgical margins

A margin is the edge of tissue cut by the surgeon. The pathologist inks these edges and examines them for tumor cells. A negative margin means none were seen at the edge. A positive margin means tumor reaches the edge and some may remain.

Negative margins lower the risk of the tumor returning in the same place, and margin status influences whether doctors add radiation after surgery. In Ewing sarcoma, unlike many bone tumors, radiation is an effective option, so a tumor in a location where surgery would cause serious harm may be treated with radiation instead.

Two findings reported in many other cancers, perineural invasion and lymphovascular invasion, are uncommon in Ewing sarcoma. They are noted when present but are not a usual part of the report.

Stage

Ewing sarcoma is staged with the TNM system, which combines the tumor itself, the lymph nodes, and spread to distant sites. Bone tumors use rules that differ by which bone is involved. For tumors of the arms and legs, the dividing line between the first two T categories is 8 centimeters.

In practice, one distinction matters far more than the stage number. Treatment and outlook turn on whether the disease is localized or has spread at diagnosis. The lungs are the commonest site of spread, followed by bone and bone marrow. This is why imaging of the chest and an assessment of the bone marrow are part of the initial workup. Lymph nodes are rarely involved.

What is the prognosis?

Outcomes in Ewing sarcoma have improved substantially with modern combination chemotherapy. A disease that was once almost always fatal is now curable in most people whose tumor has not spread.

Localized disease. Long-term cure rates are roughly 65 to 70 percent.
Complete response to chemotherapy. Associated with better outcomes than a partial response.
Disease that has spread at diagnosis, or returns early. Considerably harder to treat, with long-term survival below 30 percent.
Tumor location. Tumors of the pelvis and other central locations do less well than tumors of the arms and legs.

Larger tumors also do less well than smaller ones. These figures come from groups of patients treated over many years and cannot predict what will happen to one person. Your sarcoma team can provide numbers that match your situation.

What happens after the diagnosis?

A specialized sarcoma team at a center that treats this disease regularly manages Ewing sarcoma. Because the tumor is assumed to have spread microscopically even when scans are clear, treatment always includes chemotherapy given to the whole body, not surgery alone.

Treatment usually begins with several months of combination chemotherapy. This shrinks the tumor and treats any microscopic spread. Local treatment follows, using surgery, radiation, or both, and the choice depends on where the tumor is and what function would be lost by removing it. More chemotherapy is then given after local treatment, so the full course typically lasts most of a year.

Follow-up continues for many years, with imaging of the original site and the chest. It also covers the long-term effects of treatment on the heart, fertility, growth, and the risk of a second cancer later in life.

Questions to ask your doctor

Where is my tumor, and how large is it?
Has the cancer spread, and were my chest and bone marrow checked?
Did you do molecular testing to confirm the diagnosis?
Which fusion gene was identified, and was the partner gene named?
If only an EWSR1 result were reported, can further testing identify the partner?
Could this be one of the other round cell sarcomas rather than Ewing sarcoma?
Will local treatment be surgery, radiation, or both, and how was that decided?
After chemotherapy, was there any living tumor left in the specimen?
Were the surgical margins negative?
How long will the whole course of treatment take?
Is treatment being given as part of a clinical trial or a standard protocol?
What follow-up will I need, and for how long?
What long-term effects of treatment should I watch for?